Efg Asset Management (Americas) Corp. Xencor Inc Transaction History

Efg Asset Management (Americas) Corp.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	SELL	$25.95 - $36.95 $22,965 - $32,700	-885 Reduced 6.8%	12,125 $338,000
Q4 2022 Feb 09, 2023	SELL	$24.79 - $30.86 $19,534 - $24,317	-788 Reduced 5.71%	13,010 $338,000
Q2 2022 Jul 13, 2022	SELL	$19.74 - $29.01 $76,867 - $112,964	-3,894 Reduced 22.01%	13,798 $378,000
Q1 2022 May 05, 2022	BUY	$26.68 - $41.63 $3,308 - $5,162	124 Added 0.71%	17,692 $472,000
Q4 2021 Jan 24, 2022	BUY	$33.67 - $43.44 $11,582 - $14,943	344 Added 2.0%	17,568 $705,000
Q3 2021 Oct 22, 2021	BUY	$30.65 - $35.68 $168,483 - $196,132	5,497 Added 46.87%	17,224 $563,000
Q2 2021 Jul 23, 2021	BUY	$34.33 - $44.68 $99,179 - $129,080	2,889 Added 32.69%	11,727 $404,000
Q1 2021 Apr 09, 2021	BUY	$40.81 - $53.88 $66,153 - $87,339	1,621 Added 22.46%	8,838 $381,000
Q4 2020 Feb 05, 2021	SELL	$36.63 - $47.63 $3,809 - $4,953	-104 Reduced 1.42%	7,217 $315,000
Q3 2020 Nov 06, 2020	BUY	$30.09 - $43.02 $220,288 - $314,949	7,321 New	7,321 $284,000

199

73.7M

1.7K

4.2K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $636M
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Efg Asset Management (Americas) Corp., based on Form 13F filings with the SEC.

Stay updated on Efg Asset Management (Americas) Corp. with notifications on news.